← Back to Clinical Trials
Recruiting NCT07233447

NCT07233447 Prevalence of H. Pylori in Stomach Cancers in the West Indies

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07233447
Status Recruiting
Phase
Sponsor Centre Hospitalier Universitaire de la Guadeloupe
Condition Oncology Epidemiology
Study Type OBSERVATIONAL
Enrollment 100 participants
Start Date 2025-02-24
Primary Completion 2027-02-24

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type OBSERVATIONAL

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 100 participants in total. It began in 2025-02-24 with a primary completion date of 2027-02-24.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The incidence and mortality of stomach cancer are higher in the French West Indies than in mainland France. The prevalence of H. pylori infection associated with this cancer remains unknown in these populations. The main objective of the study is to estimate the prevalence of H. Pylori detected by immunohistochemistry in patients newly diagnosed with cancer.

Eligibility Criteria

Inclusion Criteria: * Patient over 18 years of age residing in Guadeloupe for more than 6 months and with a primary diagnosis of gastric cancer * Patient having read the information note and having signed the consent to participate in the study * Patient with social security coverage. Exclusion Criteria: * Refusal to participate. * Patient who could not answer the questionnaires * Patient not affiliated to a social security scheme * Patient under legal protection (judicial safeguard, guardianship, curatorship, etc.) * Pregnant or breastfeeding woman * Subject participating in another research study that includes an exclusion period still ongoing at the time of pre-inclusion

Contact & Investigator

Central Contact

Mélanie petapermal, Master degree

✉ melanie.petapermal@chu-guadeloupe.fr

📞 +590590934667

Principal Investigator

Jacqueline Deloumeaux, MD PhD

STUDY DIRECTOR

CHU de la Guadeloupe

Frequently Asked Questions

Who can join the NCT07233447 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Oncology Epidemiology. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT07233447 currently recruiting?

Yes, NCT07233447 is actively recruiting participants. Contact the research team at melanie.petapermal@chu-guadeloupe.fr for enrollment information.

Where is the NCT07233447 trial being conducted?

This trial is being conducted at Baie-Mahault, Guadeloupe, Pointe-à-Pitre, Guadeloupe.

Who is sponsoring the NCT07233447 clinical trial?

NCT07233447 is sponsored by Centre Hospitalier Universitaire de la Guadeloupe. The principal investigator is Jacqueline Deloumeaux, MD PhD at CHU de la Guadeloupe. The trial plans to enroll 100 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: September 2026  ·  Data Methodology